Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Bio-IT World May 2006 G. Steven Burrill	Biotech Turns in Mixed Q1 Performance Biotech closed out a rough month of March, but this did not take the shine off the exceptional performance of the mid- and small-cap biotech companies.
Bio-IT World February 2006 G. Steven Burrill	Outlook for '06, Look Back at '05 Overall, 2005 turned out to be an exceptional year for the biotech industry, but it wasn't all good news: Look Back at 2005... Predictions for 2006...
Bio-IT World August 2005 G. Steven Burrill	Biotech Outperforms Market in Q2 Heading into the summer, biotech widely outperformed the Dow and Nasdaq on a year-to-date basis. But the positive performance is attributable to a mere handful of companies driving the market.
Pharmaceutical Executive December 1, 2008 Walter Armstrong	The New Deals Everything you wanted to know about the year's most important deals, and what to watch for in the future.
The Motley Fool September 20, 2007 Brian Orelli	A Pharma Divorce, and Good Riddance Merck and Alnylam call it quits. The only real question is why the two didn't end the partnership months ago. What will it mean to investors?
The Motley Fool August 15, 2006 Ralph Casale	Sirna Battles Genes Gone Bad Pharmaceutical start-up Sirna Therapeutics tests drugs to silence rogue genes. Investors, while drugs based on RNA interference may have the potential to become the next big thing in biotechnology, they're still a long, long way from becoming FDA-approved, marketable entities.
The Motley Fool November 6, 2006 Ralph Casale	Validation for a Biotechnology Firm? How Merck's bid to buy a competitor could affect Alnylam Pharmaceuticals. With the recent run-up in share price due to the Merck offer for Sirna, investors should wait for a better price before speculating on Alnylam.
Pharmaceutical Executive May 1, 2005	Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short.
Inc. May 1, 2002 Kenneth Klee	The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies...
The Motley Fool January 25, 2005 Charly Travers	Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs.
The Motley Fool March 4, 2004 Brian Gorman	Biotech Is Back Biotech financing is on a roll. But before you jump into the sector, learn some lessons from the past. Companies that enter the market earlier in the boom are better positioned than those that start later, and it's best to choose firms with late-stage drug candidates.
Pharmaceutical Executive December 1, 2013 Peter Young	2013 Pharma and Biotech Financial Report Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better.
Bio-IT World February 10, 2003 Malorye Branca	The Art of the Deal Vertex Pharmaceuticals CEO Joshua Boger speaks about deal making and his company's success.
Pharmaceutical Executive November 1, 2011	Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk.
Pharmaceutical Executive May 1, 2007 Waseem Noor	Toolkit: How To Be a Better Partner Big pharmas and little biotechs have been getting hitched for years. Now it's time to add a little innovation to the relationship. Three new rules will keep the game exciting.
Pharmaceutical Executive May 1, 2009	The Shakeout When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game.
Bio-IT World November 2006 Kevin Davies	Merck's $1.1 Billion Bet on RNAi As if the 2006 Nobel Prize in Medicine or Physiology wasn't validation enough, Merck's acquisition of biotech firm Sirna for $1.1 billion last month offered evidence of the commercial implications of RNA interference gene-silencing technology.
The Motley Fool September 21, 2005 Rich Duprey	A Shot of Reality for Chiron Novartis warns pharma it's willing to walk away from takeover bid. Does Chiron have the wherewithal to go it alone? Investors, take note.
The Motley Fool April 4, 2006 Rich Duprey	Chiron's Booster Shot Novartis raises its bid for the biotech a second time, appeasing dissident shareholders.
Bio-IT World Jul/Aug 2006 John Russell	Burrill's Biotech 2006 G. Steven Burrill's Biotech 2006 -- Life Sciences: A Changing Prescription is his 20th annual report on the industry. This longtime market watcher and biotech investment banker has pulled together a kind of whirlwind tour of biotech finances, markets, and technologies.
The Motley Fool October 31, 2005 Rich Duprey	Chiron Not Immune to Merger The board accepts a sweetened buyout offer from Swiss pharmaceutical firm Novartis. Investors, take note.
The Motley Fool February 9, 2006 Jason Mac Gurn	RNA: Rule Breaker Nucleic Acid Investors, new RNA-based technologies may be the next revolution in biopharmaceuticals. ISIS Pharmaceuticals... Sirna Therapeutics... Alnylam Pharmaceuticals...
The Motley Fool September 7, 2005 Rich Duprey	Is Chiron Worth It? The vaccine maker rejects Novartis' bid of $40 a share as inadequate. How much should the pharma pay? Investors, take note.
BusinessWeek June 13, 2005	Biotech's "Fantastic Future Ahead" Some bold predictions on what's coming for the biotech industry from Ernst & Young's Scott Morrison.
Knowledge@Wharton March 26, 2003	Health Care Finance Industry Plagued by Lack of Funding, Focus In today's health care finance environment, early financing rounds are harder to fund and the market for initial public financings is dead, with no revival expected anytime soon.
The Motley Fool May 18, 2007 Mike Havrilla	Ample Opportunities for Alnylam The biotech's RNAi pipeline and cutting-edge technology make it a prime takeover candidate. Investors, take note.
The Motley Fool September 28, 2007 Brian Orelli	RNAi Doesn't Kill Mice After All From Merck, to AstraZeneca, to Novartis, big pharma continues to pump hundreds of millions of dollars into unproven RNAi technology. Investors, take note.
The Motley Fool January 18, 2005 Charly Travers	Biotech Class of 2004 Hot drugs are leading to amazing stock performances. CoTherix... Eyetech Pharmaceuticals... Pharmion... etc.
The Motley Fool May 24, 2011 Brian Orelli	If at First You Don't Succeed, Spin It Off Eli Lilly ditches Xigris by spinning off BioCritica.
The Motley Fool February 28, 2011 Brian Orelli	Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out?
Chemistry World September 10, 2015 Katrina Megget	Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions
The Motley Fool April 14, 2011 Frank Vinluan	Biogen Idec Inks Biotech Blood Products Research Deal With Amunix The exclusive, worldwide research collaboration agreement calls for both companies to jointly conduct preclinical research.
The Motley Fool July 14, 2005 Stephen D. Simpson	Dueling Fools: Protein Design Labs Bear Protein Design Labs could be a big winner, or a major loser. The biotech has a strong business, but today's stock price isn't "great."
Pharmaceutical Executive September 1, 2006	Finance: Good Alternatives With more ways to raise cash, biotechs with hot products can extend their independence.
The Motley Fool September 24, 2010 Brian Orelli	So Long and Thanks for All the Drug Candidates Alnylam and Novartis end their five-year partnership.
Pharmaceutical Executive July 10, 2014 William Looney	Pharm Exec's 2014 Dealmakers Outlook As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead.
The Motley Fool December 31, 2007 Brian Lawler	The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007.
Pharmaceutical Executive March 1, 2007	Finance: Q&A with Annette Grimaldi It's now more lucrative for a small pharmaceutical company to sell than to go public. Here is how the past year has shaped up - and what might be next on the horizon.
The Motley Fool January 9, 2009 Brian Orelli	Alnylam Holds Hands With a New Fella Is big pharma turning up its nose at RNAi drugs?
Pharmaceutical Executive February 1, 2007 Ben Bonifant et al.	Driven to License The competition for innovative biotech products is intense, giving rise to an unprecedented diversity of partnering strategies and an equally unprecedented convergence of small-molecule drugs and biologics in company portfolios. Licensings are shaping up as the year's big deal.
The Motley Fool December 28, 2011 Brian Orelli	Biotech Post-Holiday Regifting A pair of biotechs were on the receiving end of some holiday jeers today as their pharma partners appear to be uninterested in the drugs they were given.
Pharmaceutical Executive January 1, 2011	The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs
Pharmaceutical Executive May 1, 2014 William Looney	What's Real in Deals Recent deal making signals that the rehabilitation of big Pharma has entered a new phase aligned around a new strategic thesis: specialization and value differentiation are preferable to sheer bulk.
BusinessWeek July 12, 2004 Kerry Capell	These Biotechs Need Time To Ripen A rush to the IPO market in Europe won't do the biotech industry any good.
Pharmaceutical Executive September 1, 2008 Walter Armstrong	The M&A Numbers Young & Partners crunches pharma's filings for the first half of '08.
The Motley Fool June 14, 2005 Rich Duprey	Chiron's Credit Conundrum Standard & Poor's downgrades the biotech's credit rating on seemingly old news. Why now?
The Motley Fool July 5, 2006 Rich Duprey	Flu Vaccine Deja Vu The country's largest vaccine maker, Sanofi Aventis, gets an FDA warning letter reminiscent of the 2004 debacle.
The Motley Fool August 6, 2007 Andrew R. Vaino	NPS Pharmaceuticals: What's for Dinner? The small biotech pins its hopes on a drug that helps patients digest their food. Because the company's market cap is just $180 million, shares could jump significantly on a positive clinical result.
The Motley Fool September 7, 2005 Stephen D. Simpson	Smashing Good Deal, Eh? Glaxo's purchase of Canadian ID Biomedical will seriously augment its vaccine capabilities. Investors, take note.
The Motley Fool June 29, 2005 Karl Thiel	Cash In on the Future of Science With some diligence, you can ride your high school biology to biotech investing success.